Sangamo Therapeutics
30
1
6
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.3%
4 terminated/withdrawn out of 30 trials
82.6%
-3.9% vs industry average
0%
0 trials in Phase 3/4
47%
9 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Role: lead
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
Role: lead
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
Role: lead
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
Role: lead
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
Role: collaborator
A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Role: lead
Long-Term Follow-up of Subjects Who Were Treated With ST-920
Role: lead
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
Role: lead
Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
Role: lead
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Role: lead
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
Role: lead
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Role: lead
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
Role: lead
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Role: lead
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Role: lead
Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
Role: lead
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
Role: lead
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Role: lead
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Role: lead
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Role: lead